{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T08:59:03Z","timestamp":1776589143822,"version":"3.51.2"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Laekna Therapeutics"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-69225-2","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:15:18Z","timestamp":1770401718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Afuresertib plus fulvestrant for pretreated HR-positive, HER2-negative, advanced breast cancer: a phase Ib trial"],"prefix":"10.1038","volume":"17","author":[{"given":"Pin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-386X","authenticated-orcid":false,"given":"Tao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongsheng","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sneha","family":"Phadke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1196-8791","authenticated-orcid":false,"given":"Wenyue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4195-337X","authenticated-orcid":false,"given":"Binghe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"69225_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"69225_CR2","first-page":"47","volume":"4","author":"B Han","year":"2024","unstructured":"Han, B. et al. Cancer incidence and mortality in China, 2022. J. Natl. Cancer Cent. 4, 47\u201353 (2024).","journal-title":"J. Natl. Cancer Cent."},{"key":"69225_CR3","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1056\/NEJMoa1810527","volume":"379","author":"NC Turner","year":"2018","unstructured":"Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 926\u20131936 (2018).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR4","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","volume":"382","author":"DJ Slamon","year":"2020","unstructured":"Slamon, D. J. et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl. J. Med. 382, 514\u2013524 (2020).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR5","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr.","year":"2017","unstructured":"Sledge, G. W. Jr. et al. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875\u20132884 (2017).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR6","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","volume":"36","author":"DJ Slamon","year":"2018","unstructured":"Slamon, D. J. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J. Clin. Oncol. 36, 2465\u20132472 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR7","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","volume":"17","author":"M Cristofanilli","year":"2016","unstructured":"Cristofanilli, M. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 17, 425\u2013439 (2016).","journal-title":"Lancet Oncol."},{"key":"69225_CR8","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1038\/s41591-021-01562-9","volume":"27","author":"B Xu","year":"2021","unstructured":"Xu, B. et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat. Med. 27, 1904\u20131909 (2021).","journal-title":"Nat. Med."},{"key":"69225_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.ccell.2020.03.010","volume":"37","author":"M \u00c1lvarez-Fern\u00e1ndez","year":"2020","unstructured":"\u00c1lvarez-Fern\u00e1ndez, M. & Malumbres, M. Mechanisms of sensitivity and resistance to CDK4\/6 inhibition. Cancer Cell 37, 514\u2013529 (2020).","journal-title":"Cancer Cell"},{"key":"69225_CR10","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/9645294","volume":"2020","author":"V Lorusso","year":"2020","unstructured":"Lorusso, V., Latorre, A. & Giotta, F. Chemotherapy options beyond the first line in HER-negative metastatic breast cancer. J. Oncol. 2020, 9645294 (2020).","journal-title":"J. Oncol."},{"key":"69225_CR11","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.ccell.2021.08.009","volume":"39","author":"K Freeman-Cook","year":"2021","unstructured":"Freeman-Cook, K. et al. Expanding control of the tumor cell cycle with a CDK2\/4\/6 inhibitor. Cancer Cell 39, 1404\u20131421.e11 (2021).","journal-title":"Cancer Cell"},{"key":"69225_CR12","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1158\/1078-0432.CCR-06-2540","volume":"13","author":"S Massarweh","year":"2007","unstructured":"Massarweh, S. & Schiff, R. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities. Clin. Cancer Res. 13, 1950\u20131954 (2007).","journal-title":"Clin. Cancer Res."},{"key":"69225_CR13","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.cell.2017.04.001","volume":"169","author":"BD Manning","year":"2017","unstructured":"Manning, B. D. & Toker, A. AKT\/PKB signaling: navigating the network. Cell 169, 381\u2013405 (2017).","journal-title":"Cell"},{"key":"69225_CR14","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41571-024-00935-6","volume":"21","author":"MR Lloyd","year":"2024","unstructured":"Lloyd, M. R., Jhaveri, K., Kalinsky, K., Bardia, A. & Wander, S. A. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat. Rev. Clin. Oncol. 21, 743\u2013761 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69225_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1001\/jamaoncol.2016.0891","volume":"2","author":"SZ Millis","year":"2016","unstructured":"Millis, S. Z., Ikeda, S., Reddy, S., Gatalica, Z. & Kurzrock, R. Landscape of phosphatidylinositol-3-kinase pathway alterations across 19784 diverse solid tumors. JAMA Oncol. 2, 1565\u20131573 (2016).","journal-title":"JAMA Oncol."},{"key":"69225_CR16","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","unstructured":"Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 490, 61\u201370 (2012).","journal-title":"Nature"},{"key":"69225_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms11479","volume":"7","author":"B Pereira","year":"2016","unstructured":"Pereira, B. et al. The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat. Commun. 7, 11479 (2016).","journal-title":"Nat. Commun."},{"key":"69225_CR18","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1016\/S1470-2045(23)00676-9","volume":"25","author":"IM Browne","year":"2024","unstructured":"Browne, I. M., Andr\u00e9, F., Chandarlapaty, S., Carey, L. A. & Turner, N. C. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol. 25, e139\u2013e151 (2024).","journal-title":"Lancet Oncol."},{"key":"69225_CR19","doi-asserted-by":"publisher","first-page":"8059","DOI":"10.1158\/1078-0432.CCR-04-0035","volume":"10","author":"LA deGraffenried","year":"2004","unstructured":"deGraffenried, L. A. et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin. Cancer Res. 10, 8059\u20138067 (2004).","journal-title":"Clin. Cancer Res."},{"key":"69225_CR20","doi-asserted-by":"publisher","first-page":"4452","DOI":"10.1200\/JCO.2010.34.4879","volume":"29","author":"TW Miller","year":"2011","unstructured":"Miller, T. W., Balko, J. M. & Arteaga, C. L. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J. Clin. Oncol. 29, 4452\u20134461 (2011).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR21","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1200\/JCO.2014.60.1971","volume":"34","author":"GN Hortobagyi","year":"2016","unstructured":"Hortobagyi, G. N. et al. Correlative analysis of genetic alterations and everolimus benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: Results from BOLERO-2. J. Clin. Oncol. 34, 419\u2013426 (2016).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR22","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1056\/NEJMoa1109653","volume":"366","author":"J Baselga","year":"2012","unstructured":"Baselga, J. et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 366, 520\u2013529 (2012).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR23","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","volume":"380","author":"F Andr\u00e9","year":"2019","unstructured":"Andr\u00e9, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 380, 1929\u20131940 (2019).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41571-023-00840-4","volume":"21","author":"L Morrison","year":"2024","unstructured":"Morrison, L., Loibl, S. & Turner, N. C. The CDK4\/6 inhibitor revolution - a game-changing era for breast cancer treatment. Nat. Rev. Clin. Oncol. 21, 89\u2013105 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"69225_CR25","doi-asserted-by":"publisher","first-page":"104324","DOI":"10.1016\/j.critrevonc.2024.104324","volume":"196","author":"R Gerosa","year":"2024","unstructured":"Gerosa, R. et al. Cyclin-dependent kinase 2 (CDK2) inhibitors and others novel CDK inhibitors (CDKi) in breast cancer: clinical trials, current impact, and future directions. Crit. Rev. Oncol. Hematol. 196, 104324 (2024).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"69225_CR26","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1056\/NEJMoa2214131","volume":"388","author":"NC Turner","year":"2023","unstructured":"Turner, N. C. et al. Capivasertib in hormone receptor-positive advanced breast cancer. N. Engl. J. Med. 388, 2058\u20132070 (2023).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12282-024-01640-z","volume":"32","author":"E Tokunaga","year":"2025","unstructured":"Tokunaga, E. et al. Capivasertib and fulvestrant for patients with HR-positive\/HER2-negative advanced breast cancer: analysis of the subgroup of patients from Japan in the phase 3 CAPItello-291 trial. Breast Cancer 32, 132\u2013143 (2025).","journal-title":"Breast Cancer"},{"key":"69225_CR28","doi-asserted-by":"publisher","first-page":"S1485","DOI":"10.1016\/j.annonc.2023.10.187","volume":"34","author":"X Hu","year":"2023","unstructured":"Hu, X. et al. LBA5 Capivasertib (C) + fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+\/HER2\u2013 advanced breast cancer (ABC): Phase III CAPItello-291 trial Chinese cohort. Ann. Oncol. 34, S1485\u2013S1486 (2023).","journal-title":"Ann. Oncol."},{"key":"69225_CR29","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s40265-024-01998-6","volume":"84","author":"M Shirley","year":"2024","unstructured":"Shirley, M. Capivasertib: first approval. Drugs 84, 337\u2013346 (2024).","journal-title":"Drugs"},{"key":"69225_CR30","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s10549-021-06450-x","volume":"191","author":"N Turner","year":"2022","unstructured":"Turner, N. et al. Ipatasertib plus paclitaxel for PIK3CA\/AKT1\/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial. Breast Cancer Res. Treat. 191, 565\u2013576 (2022).","journal-title":"Breast Cancer Res. Treat."},{"key":"69225_CR31","doi-asserted-by":"crossref","unstructured":"Oliveira, M. et al. Abstract P5-16-11: Ipatasertib (ipat) in combination with palbociclib (palbo) and fulvestrant (fulv) in patients (pts) with hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC). Cancer Res. 82, P5-16-11 (2022).","DOI":"10.1158\/1538-7445.SABCS21-P5-16-11"},{"key":"69225_CR32","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1093\/annonc\/mdz086","volume":"30","author":"NC Turner","year":"2019","unstructured":"Turner, N. C. et al. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. Ann. Oncol. 30, 774\u2013780 (2019).","journal-title":"Ann. Oncol."},{"key":"69225_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1021\/acschembio.0c00872","volume":"16","author":"S Wiechmann","year":"2021","unstructured":"Wiechmann, S. et al. Chemical phosphoproteomics sheds new light on the targets and modes of action of AKT inhibitors. ACS Chem. Biol. 16, 631\u2013641 (2021).","journal-title":"ACS Chem. Biol."},{"key":"69225_CR34","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1002\/cam4.1179","volume":"6","author":"M Yamaji","year":"2017","unstructured":"Yamaji, M. et al. Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells. Cancer Med. 6, 2646\u20132659 (2017).","journal-title":"Cancer Med."},{"key":"69225_CR35","doi-asserted-by":"publisher","first-page":"e100880","DOI":"10.1371\/journal.pone.0100880","volume":"9","author":"M Dumble","year":"2014","unstructured":"Dumble, M. et al. Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor. PLoS ONE 9, e100880 (2014).","journal-title":"PLoS ONE"},{"key":"69225_CR36","doi-asserted-by":"publisher","first-page":"484493","DOI":"10.1038\/nchembio.183","volume":"5","author":"T Okuzumi","year":"2009","unstructured":"Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484493 (2009).","journal-title":"Nat. Chem. Biol."},{"key":"69225_CR37","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/bcp.13021","volume":"82","author":"PS Mundi","year":"2016","unstructured":"Mundi, P. S., Sachdev, J., McCourt, C. & Kalinsky, K. AKT in cancer: new molecular insights and advances in drug development. Br. J. Clin. Pharmacol. 82, 943\u2013956 (2016).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"69225_CR38","doi-asserted-by":"publisher","first-page":"10313","DOI":"10.1002\/anie.201502142","volume":"54","author":"J Weisner","year":"2015","unstructured":"Weisner, J. et al. Covalent-allosteric kinase inhibitors. Angew. Chem. Int. Ed. Engl. 54, 10313\u201310316 (2015).","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"69225_CR39","doi-asserted-by":"publisher","first-page":"20126","DOI":"10.1073\/pnas.1004522107","volume":"107","author":"B Miao","year":"2010","unstructured":"Miao, B. et al. Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc. Natl. Acad. Sci. USA 107, 20126\u201320131 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"69225_CR40","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1158\/1078-0432.CCR-18-2277","volume":"25","author":"SP Blagden","year":"2019","unstructured":"Blagden, S. P. et al. Phase IB dose escalation and expansion study of AKT inhibitor afuresertib with carboplatin and paclitaxel in recurrent platinum-resistant ovarian cancer. Clin. Cancer Res. 25, 1472\u20131478 (2019).","journal-title":"Clin. Cancer Res."},{"key":"69225_CR41","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1182\/blood-2014-03-559963","volume":"124","author":"A Spencer","year":"2014","unstructured":"Spencer, A. et al. The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. Blood 124, 2190\u20132195 (2014).","journal-title":"Blood"},{"key":"69225_CR42","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1832241","volume":"2022","author":"B Min","year":"2022","unstructured":"Min, B. et al. The protective mechanism of afuresertib against esophageal cancer. Dis. Markers 2022, 1832241 (2022).","journal-title":"Dis. Markers"},{"key":"69225_CR43","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1111\/ced.14798","volume":"46","author":"JH Wu","year":"2021","unstructured":"Wu, J. H. et al. The novel AKT inhibitor afuresertib suppresses human Merkel cell carcinoma MKL-1 cell growth. Clin. Exp. Dermatol. 46, 1551\u20131554 (2021).","journal-title":"Clin. Exp. Dermatol."},{"key":"69225_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01462-3","volume":"23","author":"JO Brett","year":"2021","unstructured":"Brett, J. O., Spring, L. M., Bardia, A. & Wander, S. A. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 23, 85 (2021).","journal-title":"Breast Cancer Res."},{"key":"69225_CR45","doi-asserted-by":"publisher","first-page":"PS17","DOI":"10.1158\/1538-7445.SABCS23-PS17-03","volume":"84","author":"S Howell","year":"2024","unstructured":"Howell, S. et al. Capivasertib and fulvestrant for patients with aromatase inhibitor-resistant HR positive\/HER2-negative advanced breast cancer: exploratory analysis of PFS by AKT pathway gene from the Phase 3 CAPItello-291 trial. Cancer Res. 84, PS17\u201303 (2024).","journal-title":"Cancer Res."},{"key":"69225_CR46","unstructured":"Jhaveri, K. et al. SABCS 2024 poster presentation: Capivasertib-fulvestrant for patients w\/ HR-pos\/HER2-negative advanced breast cancer who had relapsed or progressed during or after aromatase inhibitor treatment: exploratory analysis of PTEN deficiency by IHC from phase III CAPItello-291 trial."},{"key":"69225_CR47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2505725","volume":"393","author":"M Campone","year":"2025","unstructured":"Campone, M. et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer. N. Engl. J. Med. 393, 556\u2013568 (2025).","journal-title":"N. Engl. J. Med."},{"key":"69225_CR48","doi-asserted-by":"crossref","unstructured":"Jhaveri, K. L. et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N. Engl. J. Med. 392, 1189\u20131202 (2025).","DOI":"10.1056\/NEJMoa2410858"},{"key":"69225_CR49","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdz281","volume":"30","author":"N Vasan","year":"2019","unstructured":"Vasan, N., Toska, E. & Scaltriti, M. Overview of the relevance of PI3K pathway in HR-positive breast cancer. Ann. Oncol. 30, x3\u2013x11 (2019).","journal-title":"Ann. Oncol."},{"key":"69225_CR50","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris, M. A. et al. Towards targeting the breast cancer immune microenvironment. Nat. Rev. Cancer 24, 554\u2013577 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"69225_CR51","doi-asserted-by":"publisher","first-page":"PS12","DOI":"10.1158\/1538-7445.SABCS20-PS12-10","volume":"81","author":"J Masuda","year":"2021","unstructured":"Masuda, J. et al. Abstract PS12-10: phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR+, HER2- metastatic breast cancer: WJOG11418B NEWFLAME trial. Cancer Res. 81, PS12\u2013PS10 (2021).","journal-title":"Cancer Res."},{"key":"69225_CR52","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1200\/JCO.2020.38.15_suppl.1051","volume":"38","author":"HS Rugo","year":"2020","unstructured":"Rugo, H. S. et al. A phase Ib study of abemaciclib in combination with pembrolizumab for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) locally advanced or metastatic breast cancer (MBC) (NCT02779751): Interim result. J. Clin. Oncol. 38, 1051 (2020).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR53","doi-asserted-by":"publisher","first-page":"968","DOI":"10.3389\/fonc.2020.00968","volume":"10","author":"E Andreopoulou","year":"2020","unstructured":"Andreopoulou, E. et al. Akt inhibition is associated with favorable immune profile changes within the tumor microenvironment of hormone receptor positive, HER2 negative breast cancer. Front. Oncol. 10, 968 (2020).","journal-title":"Front. Oncol."},{"key":"69225_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01962-6","volume":"27","author":"M Lopez","year":"2025","unstructured":"Lopez, M. et al. Exploring the role of ESR1 mutations in metastatic hormone receptor-positive breast cancer T cell immune surveillance disruption. Breast Cancer Res. 27, 19 (2025).","journal-title":"Breast Cancer Res."},{"key":"69225_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-13992-6","volume":"25","author":"Y Ando","year":"2025","unstructured":"Ando, Y. et al. HLA class II-restricted T cell epitopes in public neoantigens of ESR1 and PIK3CA in breast cancer. BMC Cancer 25, 610 (2025).","journal-title":"BMC Cancer"},{"key":"69225_CR56","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1158\/2767-9764.CRC-23-0244","volume":"4","author":"J Goldberg","year":"2024","unstructured":"Goldberg, J. et al. Estrogen receptor mutations as novel targets for immunotherapy in metastatic estrogen receptor-positive breast cancer. Cancer Res. Commun. 4, 496\u2013504 (2024).","journal-title":"Cancer Res. Commun."},{"key":"69225_CR57","doi-asserted-by":"crossref","unstructured":"Bidard, F. C. et al. First-line camizestrant for emerging ESR1-mutated advanced breast cancer. N. Engl. J. Med. 393, 569\u2013580 (2005).","DOI":"10.1056\/NEJMoa2502929"},{"key":"69225_CR58","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","volume":"15","author":"Y Zhang","year":"2019","unstructured":"Zhang, Y. et al. Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors. Expert Opin. Drug Metab. Toxicol. 15, 767\u2013774 (2019).","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"69225_CR59","doi-asserted-by":"publisher","first-page":"32856","DOI":"10.1074\/jbc.M506119200","volume":"280","author":"E Calautti","year":"2005","unstructured":"Calautti, E., Li, J., Saoncella, S., Brissette, J. L. & Goetinck, P. F. Phosphoinositide 3-kinase signaling to Akt promotes keratinocyte differentiation versus death. J. Biol. Chem. 280, 32856\u201332865 (2005).","journal-title":"J. Biol. Chem."},{"key":"69225_CR60","first-page":"169","volume":"8","author":"W Yang","year":"2015","unstructured":"Yang, W. & Bu, H. Guideline for HER2 detection in breast cancer, the 2019 version. Chin. J. Pathol. 8, 169\u2013175 (2015).","journal-title":"Chin. J. Pathol."},{"key":"69225_CR61","unstructured":"Guideline Recommendations for Immunohistochemistry Detection in Breast Cancer Group. Guideline for testing of estrogen and progesterone receptors in breast cancer. Zhonghua Bing Li Xue Za Zhi. 44, 237\u2013239 (2015)."},{"key":"69225_CR62","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36, 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"69225_CR63","doi-asserted-by":"publisher","first-page":"545","DOI":"10.5858\/arpa.2019-0904-SA","volume":"144","author":"KH Allison","year":"2020","unstructured":"Allison, K. H. et al. Estrogen and progesterone receptor testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 144, 545\u2013563 (2020).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"69225_CR64","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"AW Chan","year":"2013","unstructured":"Chan, A. W. et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann. Intern. Med. 158, 200\u2013207 (2013).","journal-title":"Ann. Intern. Med."},{"key":"69225_CR65","doi-asserted-by":"publisher","first-page":"c332","DOI":"10.1136\/bmj.c332","volume":"340","author":"KF Schulz","year":"2010","unstructured":"Schulz, K. F., Altman, D. G. & Moher, D. CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 340, c332 (2010).","journal-title":"BMJ"},{"key":"69225_CR66","unstructured":"Predicine, Inc. PredicineCARE\u2122 CLIA Validated Pan-cancer NGS Assay [PDF]. https:\/\/www.predicine.com\/wp-content\/uploads\/2024\/12\/PredicineCARE-Flyer-APM-00001-Rev.5-13December2024.pdf (Predicine, Inc., San Carlos, 2024). Accessed August 12, 2025."},{"key":"69225_CR67","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1200\/JCO.2024.42.3_suppl.264","volume":"42","author":"T Zhang","year":"2024","unstructured":"Zhang, T. et al. Development and application of an ultra-sensitive ctDNA mutation profiling assay in monitoring therapy response and drug resistance. J. Clin. Oncol. 42, 264\u2013264 (2024).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69225-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69225-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:04:17Z","timestamp":1773677057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-69225-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["69225"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-69225-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.X. discloses receiving advisory fees from Novartis and AstraZeneca. S.P. is a consultant and scientific advisory board member for Starling Biosciences. T.F. is a speaker for AstraZeneca, Sobi, and Sanofi and discloses receiving BeyondSpring\u2019s support for travel. W.M., P.G., M.Z., and Y.Y. are employees of Laekna Therapeutics. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2456"}}